New drug trial targets Tough-to-Treat cancers that spread to the brain
NCT ID NCT06136884
Summary
This is the first study in people to test a new oral drug called AO-252 for advanced solid tumors, including cancers that have spread to the brain. The main goals are to find a safe dose and see how well the body handles the drug. It will involve about 86 adults whose cancer has worsened after at least one prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
-
Mary Crowley Cancer Research
RECRUITINGDallas, Texas, 75230, United States
Contact Email: •••••@•••••
Contact
-
Next Oncology -Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Email: •••••@•••••
-
Oklahoma Univeristy
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.